 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
Rapid Responses to:
|
|
Electronic letters published:
![[Read Rapid Response]](/icons/misc/sectionDOWN.gif){kind=icon}
Bedside diagnosing prostate cancer inherited oncological real risk and its therapy.
|
|
|||
|
Sergio Stagnaro, Researcher in Biophysical Semeiotics Biophysical Semeiotics Research Laboratory
Send rapid response to journal:
dottsergio{at}semeioticabiofisica.it Sergio Stagnaro
|
Editors, the Authors of this interesting article (1) honestly conclude: “Assessment of the comparative effectiveness and harms of localized prostate cancer treatments is difficult because of limitations in the evidence”. I ask to myself what could be therapy results when physicians all around the world will know both Oncological Terrain and INHERITED Oncological Real Isk of Prostate (2-6) In my view, based on 51 year-long clinical experience, doctors around the world have to know new and more efficacious screening types for malignancies, easy to perform on very large scale and reliable in ascertain prostate cancer "real risk" in well defined prostate lobe and prostate cancer initial stage in individuals involved by oncological terrain, of course (1). In fact, nowadays a new bed-side preventive medicine can be applied by all general practitioners worldwide in an efficient and practical manner (2-6) (See my site www.semeioticabiofisica.it, Biophysical-Semeiotic Constitutions, as well as Bibliography). As a matter of fact, today's physicians, who knows the advancements of physical semeiotics,, i.e., Quantic Biophysical Semeiotics, can bedside recognize since birth individuals at "real" risk of malignancies, both solid and liquid, including their precise location: prostate in our case. In following, I describe briefly an original physical sign, reliable in recognizing congenital "real risk" of prostate cancer, and thus useful and reliable in primary preventing it, as well as in bed-side early detecting Prostate Cancer, i.e. since very early stage, including Cancer "in situ": Massucco's sign * (2) (in above-cited website). In health, lying down on supine position and psycho-physically relaxed with open eyes aiming to prevent melatonin secretion (7), a lasting cutaneous pinch at the level of XI thoracic dermatomere, at right or left (i.e. groin regions)brings about gastric aspecific reflex (= in the stomach both fundus and body dilate, while antral-pyloric region contracts = tissue acidosis; see above-cited site, Technical Pages, n° 1), after a latency time (lt) of 8 sec. precisely.The reflex lasts “less” than 4 sec. (= paramount value, paralleling Microcirculatory Functional Reserve), and then disappears for >3 < 4 sec. (= corresponding to fractal dimension of local microcirculatory fluctuation deterministic chaos). Finally, the stomach returns to basl size. All parameters values are interesting from diagnostic point of view, but especially lt: Massucco's sign NEGATIVE. On the contrary, in case of Prostate Cancer, even in initial stage, lt is < 8 sec., reflex duration 4 sec. or more(= it plays a central role in diagnosing cancer, even initial), and finally the entire stomach contracts, i.e. Gastric tonic Contraction GtC): "pathological" pareter, typical of malignancy and rheumatic disorders, autoimmune in origin. All parameters values, indicating local prostatic micorcirculatory abnormalities (6), are in relation to the severity of underlying malignancy. For instance, lt. becomes shorter than the normal 8 sec. in inverse relation to the extension of tumour. Very useful and reliable (I perform it during physical examination, i.e. in every case, routinely) is the biophysical semeiotic "preconditioning" of prostate: after 5 sec. exactly of interval after the basal performance, doctor applies this method a second time (interval must be 5 sec. precisely, due to prostatic microcirculatory functional reserve (MFR) activation): in health, where there isn't tGC., all parameters value ameliorate significantly: e.g., latency time results 16 sec.. On the contrary, in prostate cancer, since first stages (“in situ” cancer)as well as in congenital "real risk" of cancer, they worsen clearly or persist identical in latest case (1, 2) . In my experience, the best result of therapy (I utilize Coniugated- Melatonin associated to NIR-LED, in personalized way, ) are obtained in this stage. Probably, against cancer real risk , brachytherapy, cryotherapy, photon-beam or intensity-modulated radiation therapy could be successful. The Massucco’s sign, easy to perform and reliable at the bed- side, in my view, really useful in prostate cancer clinical screening, must be included in the common physical examination, in order to early recognizing prostate cancer, also by means of a large variety of other cancer signs. In doing that, however, farsighted and clever Editors, Reviewers and physicians are unavoidable! References 1) Timothy J. Wilt, MD, MPH; Roderick MacDonald, et al. Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer. Ann. Int. Med. 18 March 2008 | Volume 0 Issue 2008 | Pages 0000605-200803180-00209-E-209 2) Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico”. Travel Factory SRL., Roma, 2004. 3)Stagnaro S., Stagnaro-Neri M., Le Costituzioni Semeiotico- Biofisiche.Strumento clinico fondamentale per la prevenzione primaria e la definizione della Single Patient Based Medicine. Ediz. Travel Factory, Roma, 2004. 4) Stagnaro Sergio. Bed-Side Prostate Cancer Detecting, even in early stages (“Real Risk” of Cancer): BMC Family Practice, 6:24 doi:10.1186/1471 -2296-6-24 http://www.biomedcentral.com/1471-2296/6/24/comments#202466 5) Stagnaro Sergio. Overloking Oncological Terrain and oncological Real Risk, no paper is up-dated! 18 January 2008 Ann. Intern Med. http://www.annals.org/cgi/eletters/147/11/775 6) Stagnaro Sergio. Oncological Terrain and Inherited Oncological Real Risk: New Way in Malignancy Primary Prevention and early Diagnosis. International Seminars in Surgical Oncology, 2007. http://www.issoonline.com/content/4/1/25/comments#290565 7) Stagnaro S., Stagnaro-Neri M., La Melatonina nella Terapia del Terreno Oncologico e del “Reale Rischio” Oncologico. Travel Factory, Roma, 2004. http://www.travelfactory.it/semeiotica_biofisica_2.htm |
|||
